Skip to content
/Costs and disease burden

Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries

Kruse C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, Wittenberg M, Lorenzl S, Richinge C, Schmotz C, Tönges L, Woitalla D, Klebe S, Bloem B R, Hommel A, Meissner W G, Laurens B, Boraud T, Foubert-Samier A, Vergnet S, Tison F, Costa N, Odin P, Rosqvist K, Norlin J M, Hjalte F, Schrag A, Dodel R

Parkinson’s disease (PD) is a neurodegenerative disease that leads to progressive disability. Cost studies have mainly explored the early stages of the disease, whereas late-stage patients are underrepresented. The aim of this study was to evaluate the resource utilization and costs of PD management in people with late-stage disease.

The Care of Late-Stage Parkinsonism (CLaSP) study collected economic data from patients with latestage PD and their caregivers in five European countries (France, Germany, the Netherlands, UK, Sweden) in a range of different settings. Patients were eligible to be included if they were in Hoehn and Yahr stage >3 in the on state or Schwab and England stage at 50% or less. In total, 592 patients met the inclusion criteria and provided information on their resource utilization. Costs were calculated from a societal perspective for a 3-month period. A least absolute shrinkage and selection operator approach was utilized to identify the most influential independent variables for explaining and predicting costs.

During the 3-month period, the costs were €20,573 (France), €19,959 (Germany), €18,319 (the Netherlands), €25,649 (Sweden), and €12,156 (UK). The main contributors across sites were formal care, hospitalization, and informal care. Gender, age, duration of the disease, Unified Parkinson’s Disease Rating Scale 2, the EQ-5D-3L, and the Schwab and England Scale were identified as predictors of costs.

Read more and download the article

Please use the search function to see what else we have done in the area of Parkinson’s Disease

Movement Disorders, 2024